Released Feb 14, 2023, after the close
10-K filed Mar 14, 2023, 73 days after period end · 0001162194-23-000013
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$27.02M$27.02M derived−29.4% vs Q4 2021+5.4% vs Q3 2022
Net Income-$20.85M-$20.85M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$21,112,000N/M
Operating Cash Flowderived-$19,181,000N/M
Free Cash Flowderived-$19,936,000N/M
Margins · derived
Operating margin-78.1%−48.7 pt vs Q4 2021
Net margin-77.1%−52.5 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $27.02M | $38.27M | $44.61M | $32.44M |
| Net Income | -$20.85M | -$9.43M | -$18.03M | -$12.69M |
| EPS Diluted | — | — | -$0.24 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR